Literature DB >> 2400393

Modulation of muscarinic-receptor expression in human embryonic lung fibroblasts by platelet-derived growth factor.

A Koman1, O Durieu-Trautmann, P O Couraud, A D Strosberg, B B Weksler.   

Abstract

Platelet-derived growth factor (PDGF) is known to have regulatory control of a large number of cellular components, including various receptors. We show that muscarinic acetylcholine receptors of the m2 subtype on CCL 137 human fibroblasts in culture are affected by PDGF treatment. A time-dependent down-regulation is observed in steady-state RNA levels, followed by a decrease in ligand-binding capacity. Minimum RNA levels are attained at 11 h; minimum binding capacity is observed after 24 h of treatment. To our knowledge, this is the first example of negative gene control by PDGF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400393      PMCID: PMC1131737          DOI: 10.1042/bj2700409

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  A human embryonic lung fibroblast with a high density of muscarinic acetylcholine receptors.

Authors:  C André; S Marullo; A Convents; B Z Lü; J G Guillet; J Hoebeke; D A Strosberg
Journal:  Eur J Biochem       Date:  1988-01-15

2.  Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes.

Authors:  E G Peralta; A Ashkenazi; J W Winslow; J Ramachandran; D J Capon
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Modulation of interleukin-1 receptor expression and interleukin-1 response in fibroblasts by platelet-derived growth factor.

Authors:  P D Bonin; J P Singh
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

5.  Low density lipoprotein receptor-dependent prostaglandin synthesis in Swiss 3T3 cells stimulated by platelet-derived growth factor.

Authors:  A J Habenicht; H A Dresel; M Goerig; J A Weber; M Stoehr; J A Glomset; R Ross; G Schettler
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes.

Authors:  A Maeda; T Kubo; M Mishina; S Numa
Journal:  FEBS Lett       Date:  1988-11-07       Impact factor: 4.124

7.  Muscarinic receptors on intact human fibroblasts. Absence of receptor activity in adult skin cells.

Authors:  D A Van Riper; M P Absher; R H Lenox
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  Regulation of transferrin receptor expression at the cell surface by insulin-like growth factors, epidermal growth factor and platelet-derived growth factor.

Authors:  R J Davis; M P Czech
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

9.  Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover.

Authors:  R Stein; R Pinkas-Kramarski; M Sokolovsky
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

10.  Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors.

Authors:  E G Peralta; A Ashkenazi; J W Winslow; D H Smith; J Ramachandran; D J Capon
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  2 in total

1.  Long-term carbachol treatment-induced down-regulation of muscarinic M2-receptors but not m2 receptor mRNA in a human lung cell line.

Authors:  E B Haddad; J Rousell; J C Mak; P J Barnes
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 2.  Pulmonary fibroblasts, an emerging target for anti-obstructive drugs.

Authors:  Kurt Racké; Susanne Haag; Amit Bahulayan; Mareille Warnken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-13       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.